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Abstract
Background: To empirically evaluate bias in estimation of accuracy associated with delay in
verification of diagnosis among studies evaluating tests for predicting endometrial hyperplasia.
Methods: Systematic reviews of all published research on accuracy of miniature endometrial
biopsy and endometr ial ultrasonography for diagnosing endometrial hyperplasia identified 27 test
accuracy studies (2,982 subjects). Of these, 16 had immediate histological verification of diagnosis
while 11 had verification delayed > 24 hrs after testing. The effect of delay in verification of diagnosis
on estimates of accuracy was evaluated using meta-regression with diagnostic odds ratio (dOR) as
the accuracy measure. This analysis was adjusted for study quality and type of test (miniature
endometrial biopsy or endometrial ultrasound).
Results: Compared to studies with immediate verification of diagnosis (dOR 67.2, 95% CI 21.7–
208.8), those with delayed verification (dOR 16.2, 95% CI 8.6–30.5) underestimated the diagnostic
accuracy by 74% (95% CI 7%–99%; P value = 0.048).
Conclusion:  Among studies of miniature endometrial biopsy and endometrial ultrasound,
diagnostic accuracy is considerably underestimated if there is a delay in histological verification of
diagnosis.
Background
The natural history of endometrial hyperplasia is not fully
understood [1]. What is known is that a proportion of
simple and complex hyperplastic processes will regress
without treatment [2] although the time scale over which
such regression may occur is unclear. Similarly the time
scale over which benign endometrium progresses to
hyperplasia is also unknown. Among studies evaluating
accuracy of tests for diagnosis of hyperplasia (miniature
biopsy or ultrasonography), it has previously been
hypothesised that if histological verification of diagnosis
after performing the test is delayed, the estimation of test
accuracy may be influenced by the phenomena of disease
regression or progression [3]. For instance, false positive
diagnoses of endometrial hyperplasia may occur due to
natural disease regression during the time interval
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between testing and verification of diagnosis. Similarly,
false negative diagnoses may also result from progression
of benign functional or atrophic endometrium.
To obtain accurate estimates of test accuracy in studies of
hyperplasia, an immediate comparison of the test under
scrutiny with a reference standard that verifies the diagno-
sis will be essential [4-6]. When accuracy studies suffer
from a delay in performance of the reference standard, the
resultant false positives and false negatives will be
expected to lead to an underestimation of test accuracy. In
systematic reviews, when studies of various designs are
collated, the extent of underestimation that arises from
delay is important in obtaining an unbiased pooled accu-
racy estimate. To our knowledge, the extent of underesti-
mation of accuracy due to a delay in verification of
diagnosis has not been evaluated empirically in studies of
endometrial hyperplasia. We undertook this analysis to
examine formally how inaccurate the estimation of accu-
racy can be in studies evaluating miniature endometrial
biopsy devices and endometrial thickness measurement
by pelvic ultrasonography for predicting endometrial
hyperplasia when there are delays in histological verifica-
tion of diagnosis.
Methods
To test our hypothesis, a data set of all the published stud-
ies reporting the accuracy of miniature endometrial
biopsy devices and endometrial ultrasonography for pre-
dicting endometrial hyperplasia was obtained from sys-
tematic reviews [7,8]. The reviews focused on test accuracy
studies in which the results of the test were compared with
the results of a reference standard. The targeted popula-
tion was women with abnormal pre- or postmenopausal
uterine bleeding. The diagnostic tests of interest were min-
iature endometrial biopsy devices (for example, pipelle®
endometrial suction curette, Unimar, Wilton, CT, USA)
and endometrial thickness measurement by pelvic ultra-
sonography. The reference standard was endometrial his-
tology obtained by an independent endometrial sampling
technique, for example, inpatient curettage (with hyster-
oscopy) or hysterectomy.
Identification of studies
Two independent electronic searches of MEDLINE and
EMBASE were conducted to identify relevant citations on
endometrial biopsy (1980–1999) and ultrasonography
(1966–2000). Search term combination for endometrial
biopsy [8] was diagnosis (MeSH) AND endometrial biopsy
(textword), while that for studies on ultrasonography [7]
was ultrasound AND endometrial thickness AND sonography
(textwords). The searches were limited to human studies,
but there were no language restrictions. Relevant studies
were identified by examining all the retrieved citations,
reference lists of all known reviews and primary studies,
and direct contact with manufacturers. Details of the
search and selection processes can be found in the pub-
lished reports of the reviews [7,8].
Study quality assessment
All selected studies were assessed for their methodological
quality defined as the confidence that study design, con-
duct and analysis minimize bias in the estimation of diag-
nostic accuracy [9-11]. We considered the following
features in quality assessment: method of recruitment of
sample, appropriateness of patient spectrum, and blind-
ing of comparison between test and reference standard.
Recruitment was considered to be adequate if patient
selection was consecutive or a random sample was
obtained. Patient spectrum was considered to be appro-
priate if both pre- and postmenopausal women were
included. Blinding was considered to be present if it was
clearly reported that the pathologists providing histologi-
cal reports were kept unaware of the results of miniature
endometrial biopsy or endometrial ultrasonography. If
the results of the diagnostic tests were divulged to the
pathologists or in the absence of any such reporting,
blinding was categorised as absent. For the purpose of our
analysis, studies were classified into two quality catego-
ries: Category I studies had any one of the following fea-
tures: adequate recruitment, appropriate spectrum, and
blinding; category II studies had none of the above quality
features.
Data extraction
In addition to assessment of methodological quality, data
were extracted to allow classification of studies into one of
two groups: i) immediate verification – reference standard
performed within 24 hours of testing, and ii) delayed ver-
ification – reference standard performed more than 24
hours after testing. Any studies that could not be catego-
rised in this way due to lack of reporting were excluded.
Data were then abstracted as 2 × 2 tables and estimates of
diagnostic accuracy were derived for each individual
study. A correction factor of 0.5 was used when cells of the
2 × 2 tables included zero values [12]. True positive rates
(sensitivity), false positive rates (1-specificity) and diag-
nostic odds ratios (dORs) were calculated for each pri-
mary evaluation. The dOR represents a ratio of the
positive and negative likelihood ratios and it can be math-
ematically summarised as:
dOR = [sensitivity/(1-specificity)] / [(1-sensitivity)/specif-
icity]
Statistical analysis
Pooled dORs were generated as the principal measures of
diagnostic accuracy. Meta-analyses to produce summary
estimates of accuracy were performed separately for sub-
groups of studies reporting immediate and delayedBMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/18
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verification. To delineate the impact of delay in verifica-
tion of diagnosis, weused meta-regression analysis
[13,14] with the log of dOR as the accuracy measure. This
technique fitted a multivariable linear regression model
for examining the influence of delay, quality and test type
on the estimation of accuracy observed among studies
included in the analysis (random effects model). In this
way the analysis was adjusted for the confounding effects
of study quality (two quality categories) and type of test
(miniature endometrial biopsy or endometrial
ultrasound).
Results
Selection of studies
The study selection process is shown in Figure 1. In total
there were 2,982 subjects in 27 diagnostic evaluations
reported in the 24 eligible primary studies. Eleven evalua-
tions delayed verification of the diagnosis by more than
24 hours; the delay was up to six months in one study, up
to four weeks in four studies, up to three weeks in one
study and up to one week in the remaining three studies.
Three of these studies were rated as category I for method-
ological quality, and eight as category II. Sixteen evalua-
tions verified the diagnosis within 24 hours of the test.
Among these, seven studies were rated as category I for
quality, and nine as category II (Table 1).
Table 2 shows the diagnostic accuracy results for individ-
ual studies according to test type and verification status in
terms of delay. The summary statistics for the various sub-
groups showed that the dOR for studies with immediate
verification was 67.2 (21.7–208.8) while that for studies
with delayed verification was 16.2 (8.6–30.5) as shown in
Figure 2. Meta-regression analysis for bias due to delay in
verification of diagnosis, adjusted for study quality and
test type, showed that the underestimation of test accuracy
among studies with delayed verification was 74% (95%
CI 7%-99%; P = 0.048) on average compared to studies
with immediate verification (Table 3).
Discussion
Our study shows empirically the magnitude of bias asso-
ciated with delay in verification of diagnosis in test accu-
racy studies. Delay in verification of more than 24 hours
was associated with a considerable underestimation of
accuracy of miniature biopsy and endometrial ultrasonog-
raphy in diagnosing endometrial hyperplasia. This sup-
ports the premise that the reported limited accuracy of
miniature endometrial biopsy devices and endometrial
ultrasonography in diagnosing hyperplasia is due, in part,
to natural history of disease rather than resulting entirely
from intrinsic problems with performance of the diagnos-
tic tools [3].
We posed our hypothesis a priori and tested it in as rigor-
ous a manner as possible. Our literature search was with-
out language restriction, facilitating retrieval of many
relevant test accuracy studies. However, due to poverty of
reporting many critical pieces of information were miss-
ing in the available literature, restricting the number of
studies that could be included in our analysis (for exam-
ple, 31 studies were ineligible for inclusion because
explicit information about time before verification was
omitted). Our examination of delays in verification was
also restricted; just two time categories were discernible
(delay < 24 hours or > 24 hours). Immediate verification
(reference standard to be performed straight after the
index test) was not achievable in some studies because the
reference test (inpatient endometrial sampling) necessi-
tated use of general anaesthesia. A practical cut-off of 24
hours was taken to allow time for reference testing to be
undertaken when the preceding index tests (miniature
endometrial biopsy and ultrasound) were performed in
the conscious outpatient. Although the natural history of
endometrial hyperplasia is unclear, it is unlikely that bio-
logical alteration would have occurred within 24 hours.
To study the rate of disease progression or regression
would require repeated testing over time, but such a study
is unlikely to be ethically justifiable, given that most clini-
cians will institute treatment following initial diagnosis.
Such a study would be then become one of prognosis
under treatment rather than a natural history study.
We also evaluated other features of methodological qual-
ity and, in general, found the quality of studies to be poor.
For example, only three studies reported blinding inter-
pretation of the reference test from knowledge of results
from the index test. A lack of blinding can introduce bias
and overestimation of diagnostic accuracy [4]. Pathologi-
cal interpretation of endometrial hyperplasia is open to a
varying degree of subjectivity especially at extreme ends of
the spectrum, where overlap with benign functional
endometrium (simple hyperplasia) and cancer (complex
hyperplasia with cytological atypia) is more likely.
Absence (or explicit reporting) of blinding is thus associ-
ated with poorer methodological quality and this feature
was incorporated in our quality assessment. Our analysis
adjusted for the confounding effects of quality but our
inferences should be interpreted with caution due to rela-
tive scarcity of good quality studies.
Conclusions
Our findings have implications for research into new
diagnostic interventions. Our results demonstrate that test
evaluation with robust study design (immediate verifica-
tion) showed good test performance but evaluation in
poor designs (delayed verification) showed poor perform-
ance. Poor designs may reflect the situation prevalent in
routine clinical practice where test results may not beBMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/18
Page 4 of 8
(page number not for citation purposes)
Flow diagram showing study selection process Figure 1
Flow diagram showing study selection process.
Endometrial biopsy  Ultrasound
Number of potentially eligible studies 
from search (see methods) n=52
Number of potentially eligible 
studies from search n=145
Number of studies included in 
systematic review n=9
Excluded studies n=0
Number of studies included in 
systematic review n=57
Excluded studies n=42
Reason for exclusion from present 
study:
Reference standard not obtained by 
an independent, endometrial 
sampling technique n=0
Absence of explicit information on 
time between test performance and 
verification n=31 
Both of the above n=11
Number of studies (and evaluations) 
eligible for inclusion in present study
n=9 (12)
Number of studies (and evaluations) 
eligible for inclusion in present study
n=15 (15)
Total studies (and evaluations) 
included in present study n= 24 (27)BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/18
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Table 1: Study characteristics and methodological quality.
Bleeding type / Menopausal status (%)
Study (Year 
published)
Details Delay 
(hours)
Patient 
selection
Post HRT Pre †Other Reference 
standard
Blinding 
of results
Study 
quality 
level
IMMEDIATE VERIFICATION (</=24 HOURS) (16 studies)
Endometrial biopsy studies (8)
Sun-Kuie et al. 
[15] (1992)
Gynoscann® Day before Unreported *5 (11) - 41 (89) - D&C Unreported I
Goldberg et al. 
[16] (1981)
Accurette® Immediate Unreported 30 (100) - - D&C Unreported II
Sonnendecker 
et al. [17]  
(1981)
Accurette® Immediate Unreported *6 (24) - 17 (76) - D&C Unreported I
Kufahl et al. 
[18] (1997)
Explora® Immediate Consecutive *33 (21) - 125 (79) - Hysterectomy Unreported I
Kufahl et al.  
[18] (1997)
Gynoscann® Immediate Consecutive *36 (21) - 133 (79) - Hysterectomy Unreported I
Goldschmit et 
al.  [19] (1993)
Pipelle® Immediate Consecutive *34 (23) - 115 (77) - D&C Yes I
Kavak et al.  
[20] (1996)
Pipelle® Immediate Unreported *34 (56) - 27 (44) - D&C Yes I
Goldberg et al.  
[16] (1981)
Vabra 
Aspirator®
Immediate Unreported 31 (100) - - - D&C Unreported II
Ultrasound scan studies (8)
Botsis et al. 
[21] (1992)
≤ 4 mm DL Day before Unreported 120(100) - - - D&C Unreported II
Garuti et al.  
[22] (1999)
≤ 4 mm DL Immediate Unreported 368 (88) 51 
(12)
- - D&C Unreported I
Haller et al.  
[23](1996)
≤ 4 mm DL Day before Unreported 81 (100) - - - D&C Unreported II
Grigoriou et al.  
[24] (1996)
≤ 5 mm DL Day before Unreported 250(100) - - - D&C Unreported II
Karlsson et al.  
[25](1993)
≤ 5 mm DL Day before Unreported 103(100) - - - D&C Unreported II
Malinova et al.  
[26] (1996)
≤ 5 mm DL Day before Unreported 154(100) - - - D&C Unreported II
Wolman et al.  
[27] (1996)
≤ 5 mm DL Immediate Unreported 54 (100) - - - D&C Unreported II
Malinova et al.  
[28] (1995)
≤ 5 mm SL Day before Unreported 118(100) - - - D&C Unreported II
DELAYED VERIFICATION (> 24 HOURS) (11 studies)
Endometrial biopsy studies (4)
Stovall et al. 
[29] (1989)
Novak 
Curette®
Unreported Unreported - - - 165(100) NS Hysterectomy Unreported II
Krampl et al. 
[3] (1997)
Pipelle® < 6 months Unreported 37 (12) - 247 (77) 35 (11) TCRE/
Hysterectomy
Unreported I
Gupta et al. 
[30] (1996)
Pipelle® < 1 month Unreported 54 (100) - - D&C Unreported II
Stovall et al. 
[29]  (1989)
Vabra 
Aspirator®
Unreported Unreported - - - 62 (100) NS Hysterectomy Unreported IIBMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/18
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Ultrasound scan studies (7)
Guner et al.  
[31](1996)
≤ 4 mm DL </= 7 days Unreported 192(100) - - - D&C Unreported II
Abu-Ghazzeh 
et al.  [32] 
(1999)
≤ 5 mm DL 1 week Unreported 98 (100) - - - D&C Unreported II
DeSilva et al.  
[33] (1997)
≤ 5 mm DL < 4 weeks Consecutive 44 (88) 6 (12) - - D&C Unreported I
Gupta et al.  
[30] (1996)
≤ 5 mm DL < 1 month Unreported 75 (100) - - - D&C Yes I
Taviani et al.  
[34] (1995)
≤ 5 mm DL 1 week Unreported 41 (100) - - - D&C Unreported II
Moreles et al.  
[35] (1998)
≤ 6 mm DL < 3 weeks Unreported 200(100) - - - D&C Unreported II
Mortakis et al.  
[36] (1997)
≤ 3 mm SL < 4 weeks Unreported 78 (100) - - - D&C Unreported II
*Numbers calculated from initial proportion of patients within these groups before missing outcome data was excluded. †Other refers to 
proportion of women included in the study who did not have abnormal uterine bleeding as an indication for investigation. HRT, hormone 
replacement therapy; NS, not specified (refers to proportion of women included in the study where the type of abnormal uterine bleeding was not 
specified); DB, directed biopsy; D&C, dilatation and curettage; TCRE, transcervical resection of the endometrium; DL, double layer endometrial 
thickness; SL, single layer endometrial thickness.
Effect of delayed verification on the diagnostic accuracy of miniature endometrial biopsy and transvaginal ultrasound in detect- ing endometrial hyperplasia Figure 2
Effect of delayed verification on the diagnostic accuracy of miniature endometrial biopsy and transvaginal ultrasound in detect-
ing endometrial hyperplasia. Pooled diagnostic odds ratios (dOR) for studies with immediate and delayed verification.
Table 1: Study characteristics and methodological quality. (Continued)
2000 1000 500 200 100 50 20 10
DOR (logarithmic scale)
Delayed verification
Endometrial biopsy (n=8)
Ultrasound scan (n=7)
Total (n=11)
Total (n=16)
Ultrasound scan (n=8)
Endometrial biopsy (n=8)
Immediate verification dOR (95% CI)
173.9 (20.0 – 1512.5)
30.6 (9.1 – 102.6)
67.2 (21.7 – 208.8)
24.9 (6.6 – 93.7)
15.6 (7.1 – 34.1)
16.2 (8.6 – 30.5)BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/18
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immediately confirmed due to resource and other impli-
cations. Thus diagnostic evaluations carried out in routine
practice may mask the accuracy of tests.
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Table 2: Accuracy stratified by time delay between test performance and confirmation by chosen reference test histology.
Device (no. evaluations) & 
study (year published)
+ve test (sensitivity) -ve test (1-specificity) Odds ratio (95% CI)
IMMEDIATE VERIFICATION (</= 24 HOURS) (16 studies)
Endometrial biopsy studies (8)
Sun-Kuie et al.  [15](1992) 2/4 (0.5) 0/42 (0.0) 85.0 (3.2–2289.6)
Goldberg et al. [16] (1981) 5/5 (1.0) 0/25 (0.0) 561.0 (10.0–31463.1)
Sonnendecker et al. [17] (1981) 2/2 (1.0) 0/21 (0.0) 215.0 (3.5–13408.5)
Kufahl et al. [18] (1997) 14/15 (0.9) 4/143 (0.03) 486.5 (50.8–4658.5)
Kufahl et al.  [18](1997) 3/15 (0.2) 15/154 (0.1) 2.3 (0.6–9.1)
Goldschmit et al.  [19] (1993) 11/14 (0.8) 1/135 (0.01) 491.3 (47.1–5127.3)
Kavak et al.  [20] (1996) 4/4 (1.0) 0/57 (0.0) 1035.0 (18.3–58563.1)
Goldberg et al.  [16] (1981) 6/6 (1.0) 0/25 (0.0) 663.0 (12.0–36690.0)
Ultrasound scan studies (8)
Botsis et al. [21] (1992) 10/10 (1.0) 4/92 (0.04) 413.0 (20.8–8221.1)
Garuti et al.  [22] (1999) 44/46 (0.96) 196/313 (0.63) 13.1 (3.1–55.2)
Haller et al. [23] (1996) 14/16 (0.88) 34/49 (0.69) 3.1 (0.6–15.3)
Grigoriou et al.  [24]  (1996) 45/45 (0.98) 30/181 (0.17) 452.0 (27.1–7538.5)
Karlsson et al.  [25]  (1993) 10/10(1.0) 21/78 (0.27) 56.2 (3.2–1000.5)
Malinova et al.  [26]  (1996) 11/11 (1.0) 32/74 (0.43) 30.1 (1.7–529.5)
Wolman et al.  [27]  (1996) 10/11(0.91) 12/39 (0.31) 22.5 (2.6–196.1)
Malinova et al.  [28]  (1995) 7/7 (1.0) 19/54 (0.35) 27.31 (1.5–504.1)
DELAYED VERIFICATION (> 24 HOURS) (11 studies)
Endometrial biopsy studies (4)
Stovall et al.  [29]  (1989) 8/16 (0.5) 4/149 (0.03) 36.3 (9.0–146.3)
Krampl et al. [3]  (1997) 14/35 (0.4) 24/284(0.0) 7.2 (3.3–16.0)
Gupta et al. [30]  (1996) 6/10 (0.6) 1/44 (0.02) 64.5 (6.1–677.6)
Stovall et al. [29]  (1989) 7/7 (1.0) 7/55 (0.13) 97.0 (5.0–1879.9)
Ultrasound scan studies (7)
Guner et al.  [31]  (1996) 31/31 (1.0) 61/142 (0.43) 83.5 (5.0–1391.3)
Abu-Ghazzeh et al.  [32]  (1999) 2/2 (1.0) 58/95 (0.61) 3.2 (0.2–68.6)
DeSilva et al.  [33]  (1997) 2/3 (0.67) 10/44 (0.23) 6.8 (0.6–83.0)
Gupta et al.  [30] (1996) 4/4 (1.0) 22/68 (0.32) 18.6 (1.0–360.7)
Taviani et al.  [34] (1995) 2/2 (1.0) 16/37 (0.43) 6.5 (0.3–145.1)
Moreles et al.  [35]  (1998) 33/37 (0.9) 37/143 (0.26) 23.6 (7.8–71.2)
Mortakis et al.  [36]  (1997) 4/5 (0.8) 26/66 (0.39) 6.2 (0.7–58.2)
Table 3: Results of meta-regression analysis.
Outcome Explanatory variables Univariable analysis Multivariable analysis
Ratio dOR (95% CI)† P value Ratio dOR (95% CI)† P value
Endometrial hyperplasia
▪ Delay in verification of diagnosis (> 24 hours vs. < 24 hours) 0.31 (0.08–0.84) 0.089 0.26 (0.07–0.99) 0.048
▪ Study quality (category II vs. category I) 1.36 (0.34–5.53) 0.664 3.46 (0.79–15.0) 0.098
▪ Test (Endometrial biopsy vs. ultrasound endometrial thickness) 3.22 (0.83–12.55) 0.091 5.0 (1.2–20.7) 0.027
†The dependent variable is the natural logarithm of the diagnostic odds ratio (dOR). Results are presented as the ratio of diagnostic odds ratios 
(RdOR); an RdOR < 1 means that the diagnostic accuracy is reduced and a RdOR > 1 means that it is increased in relation to the reference 
category, < 24 h, category I, and ultrasound endometrial thickness, respectively.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/18
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